Gan & Lee Pharmaceuticals バランスシートの健全性

財務の健全性基準チェック /66

Gan & Lee Pharmaceuticalsの総株主資本はCN¥11.2B 、総負債はCN¥0.0で、負債比率は0%となります。総資産と総負債はそれぞれCN¥12.2BとCN¥1.0Bです。 Gan & Lee Pharmaceuticalsの EBIT はCN¥249.6Mで、利息カバレッジ比率-2です。現金および短期投資はCN¥5.1Bです。

主要情報

負債資本比率

CN¥0

負債

インタレスト・カバレッジ・レシオ	-2x
現金	CN¥5.07b
エクイティ	CN¥11.21b
負債合計	CN¥1.01b
総資産	CN¥12.22b

財務の健全性に関する最新情報

更新なし

Recent updates

Shareholders In Gan & Lee Pharmaceuticals (SHSE:603087) Should Look Beyond Earnings For The Full Story

Sep 04

Analysts Just Shipped A Sizeable Upgrade To Their Gan & Lee Pharmaceuticals. (SHSE:603087) Estimates

Apr 29

Some Confidence Is Lacking In Gan & Lee Pharmaceuticals.'s (SHSE:603087) P/S

Mar 01

財務状況分析

短期負債: 603087の短期資産 ( CN¥6.5B ) が短期負債 ( CN¥806.7M ) を超えています。

長期負債: 603087の短期資産 ( CN¥6.5B ) が長期負債 ( CN¥208.1M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: 603087は負債がありません。

負債の削減: 603087 5 年前には負債がありませんでした。

債務返済能力: 603087には負債がないため、営業キャッシュフローでカバーする必要はありません。

インタレストカバレッジ: 603087には負債がないため、利息支払いの負担は問題になりません。

Gan & Lee Pharmaceuticals バランスシートの健全性

財務の健全性 基準チェック /66

主要情報

財務の健全性に関する最新情報

Recent updates

Gan & Lee Pharmaceuticals Announces Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks

Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Gan & Lee Pharmaceuticals. to Report Q3, 2024 Results on Oct 23, 2024

Investor sentiment improves as stock rises 18%

Gan & Lee Pharmaceuticals. (SHSE:603087) announces an Equity Buyback for CNY 300 million worth of its shares.

Shareholders In Gan & Lee Pharmaceuticals (SHSE:603087) Should Look Beyond Earnings For The Full Story

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Gan & Lee Pharmaceuticals. to Report First Half, 2024 Results on Aug 29, 2024

Price target increased by 7.8% to CN¥62.50

Analysts Just Shipped A Sizeable Upgrade To Their Gan & Lee Pharmaceuticals. (SHSE:603087) Estimates

Gan & Lee Pharmaceuticals., Annual General Meeting, May 16, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Gan & Lee Pharmaceuticals. to Report Q1, 2024 Results on Apr 25, 2024

Some Confidence Is Lacking In Gan & Lee Pharmaceuticals.'s (SHSE:603087) P/S

Gan & Lee Pharmaceuticals. to Report Fiscal Year 2023 Results on Apr 25, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.39 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.55 loss in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.09 (vs CN¥0.20 in 1Q 2022)

Gan & Lee Pharmaceuticals.(XSSC:603087) dropped from FTSE All-World Index (USD)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.39 loss per share (vs CN¥0.90 profit in 3Q 2021)

Gan & Lee Pharmaceuticals. announced that it expects to receive CNY 813.6 million in funding

Investor sentiment improved over the past week

Second quarter 2022 earnings released: CN¥0.55 loss per share (vs CN¥0.32 profit in 2Q 2021)

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Gan & Lee Pharmaceuticals Co., Ltd. Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18

Third quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.70 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.34 in 2Q 2020)

Investor sentiment deteriorated over the past week

Gan & Lee Pharmaceuticals Co., Ltd. Announces Positive Phase 1 Clinical Trial Results at the 81st Scientific Sessions of the American Diabetes Association

First quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.24 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥2.31 (vs CN¥2.31 in FY 2019)

New 90-day low: CN¥121

FDA Grants Fast Track Designation for Gan & Lee Pharmaceuticals Co., Ltd.'s GLR2007, for the Treatment of Patients with Glioblastoma

Investor sentiment improved over the past week

New 90-day high: CN¥174

Investor sentiment improved over the past week

New 90-day high: CN¥136

New 90-day low: CN¥115

Third quarter earnings released

Earnings released

Gan & Lee Pharmaceutical, Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Gan & Lee Pharmaceutical, Ltd. announced that it has received funding from Hillhouse Capital Management, Ltd.

財務状況分析

デット・ツー・エクイティの歴史と分析

貸借対照表

健全な企業の発掘

財務の健全性基準チェック /66